Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States—a retrospective study

Sanjaya Satapathy, Yu Jiang, James D. Eason, Satish K. Kedia, Emily Wong, Ashwani K. Singal, Elizabeth Tolley, Donna Hathaway, Satheesh Nair, Jason M. Vanatta

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Nonalcoholic steatohepatitis (NASH) has become an increasingly important indication for liver transplantation (LT), and there has been a particular concern of excessive cardiovascular-related mortality in this group. Using the United Network for Organ Sharing-Standard Transplant Analysis and Research (UNOS STAR) dataset, we reviewed data on 56,995 adult transplants (January 2002 through June 2013). A total of 3,170 NASH liver-only recipients were identified and were matched with 3,012 non-NASH HCV+ and 3,159 non-NASH HCV− controls [matched 1:1 based on gender, age at LT (±3 years), and MELD score (±3)]. Cox regression analysis revealed significantly lower hazard of all-cause (HR 0.669; P < 0.0001) and cardiovascular-related mortality (HR 0.648; P < 0.0001) in the NASH compared to the non-NASH group after adjusting for diabetes, BMI, and race. Relative to the non-NASH HCV-positive group, NASH group has lower hazard of all-cause (HR 0.539; P < 0.0001) and cardiovascular-related mortality (HR 0.491; P < 0001). A lower hazard of all-cause mortality (HR 0.844; P = 0.0094) was also observed in NASH patients compared to non-NASH HCV-negative group, but cardiovascular mortality was similar (HR 0.892; P = 0.3276). LT recipients with NASH have either lower or similar risk of all-cause and cardiovascular-related mortality compared to its non-NASH counterparts after adjusting for diabetes, BMI, and race.

Original languageEnglish (US)
Pages (from-to)1051-1060
Number of pages10
JournalTransplant International
Volume30
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Fatty Liver
Retrospective Studies
Mortality
Liver
Liver Transplantation
Transplants
Transplant Recipients
Non-alcoholic Fatty Liver Disease
Regression Analysis
Research

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States—a retrospective study. / Satapathy, Sanjaya; Jiang, Yu; Eason, James D.; Kedia, Satish K.; Wong, Emily; Singal, Ashwani K.; Tolley, Elizabeth; Hathaway, Donna; Nair, Satheesh; Vanatta, Jason M.

In: Transplant International, Vol. 30, No. 10, 01.10.2017, p. 1051-1060.

Research output: Contribution to journalArticle

Satapathy, Sanjaya ; Jiang, Yu ; Eason, James D. ; Kedia, Satish K. ; Wong, Emily ; Singal, Ashwani K. ; Tolley, Elizabeth ; Hathaway, Donna ; Nair, Satheesh ; Vanatta, Jason M. / Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States—a retrospective study. In: Transplant International. 2017 ; Vol. 30, No. 10. pp. 1051-1060.
@article{4b6a978855ad4361a2b3c6c4f2a07740,
title = "Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States—a retrospective study",
abstract = "Nonalcoholic steatohepatitis (NASH) has become an increasingly important indication for liver transplantation (LT), and there has been a particular concern of excessive cardiovascular-related mortality in this group. Using the United Network for Organ Sharing-Standard Transplant Analysis and Research (UNOS STAR) dataset, we reviewed data on 56,995 adult transplants (January 2002 through June 2013). A total of 3,170 NASH liver-only recipients were identified and were matched with 3,012 non-NASH HCV+ and 3,159 non-NASH HCV− controls [matched 1:1 based on gender, age at LT (±3 years), and MELD score (±3)]. Cox regression analysis revealed significantly lower hazard of all-cause (HR 0.669; P < 0.0001) and cardiovascular-related mortality (HR 0.648; P < 0.0001) in the NASH compared to the non-NASH group after adjusting for diabetes, BMI, and race. Relative to the non-NASH HCV-positive group, NASH group has lower hazard of all-cause (HR 0.539; P < 0.0001) and cardiovascular-related mortality (HR 0.491; P < 0001). A lower hazard of all-cause mortality (HR 0.844; P = 0.0094) was also observed in NASH patients compared to non-NASH HCV-negative group, but cardiovascular mortality was similar (HR 0.892; P = 0.3276). LT recipients with NASH have either lower or similar risk of all-cause and cardiovascular-related mortality compared to its non-NASH counterparts after adjusting for diabetes, BMI, and race.",
author = "Sanjaya Satapathy and Yu Jiang and Eason, {James D.} and Kedia, {Satish K.} and Emily Wong and Singal, {Ashwani K.} and Elizabeth Tolley and Donna Hathaway and Satheesh Nair and Vanatta, {Jason M.}",
year = "2017",
month = "10",
day = "1",
doi = "10.1111/tri.13001",
language = "English (US)",
volume = "30",
pages = "1051--1060",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States—a retrospective study

AU - Satapathy, Sanjaya

AU - Jiang, Yu

AU - Eason, James D.

AU - Kedia, Satish K.

AU - Wong, Emily

AU - Singal, Ashwani K.

AU - Tolley, Elizabeth

AU - Hathaway, Donna

AU - Nair, Satheesh

AU - Vanatta, Jason M.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Nonalcoholic steatohepatitis (NASH) has become an increasingly important indication for liver transplantation (LT), and there has been a particular concern of excessive cardiovascular-related mortality in this group. Using the United Network for Organ Sharing-Standard Transplant Analysis and Research (UNOS STAR) dataset, we reviewed data on 56,995 adult transplants (January 2002 through June 2013). A total of 3,170 NASH liver-only recipients were identified and were matched with 3,012 non-NASH HCV+ and 3,159 non-NASH HCV− controls [matched 1:1 based on gender, age at LT (±3 years), and MELD score (±3)]. Cox regression analysis revealed significantly lower hazard of all-cause (HR 0.669; P < 0.0001) and cardiovascular-related mortality (HR 0.648; P < 0.0001) in the NASH compared to the non-NASH group after adjusting for diabetes, BMI, and race. Relative to the non-NASH HCV-positive group, NASH group has lower hazard of all-cause (HR 0.539; P < 0.0001) and cardiovascular-related mortality (HR 0.491; P < 0001). A lower hazard of all-cause mortality (HR 0.844; P = 0.0094) was also observed in NASH patients compared to non-NASH HCV-negative group, but cardiovascular mortality was similar (HR 0.892; P = 0.3276). LT recipients with NASH have either lower or similar risk of all-cause and cardiovascular-related mortality compared to its non-NASH counterparts after adjusting for diabetes, BMI, and race.

AB - Nonalcoholic steatohepatitis (NASH) has become an increasingly important indication for liver transplantation (LT), and there has been a particular concern of excessive cardiovascular-related mortality in this group. Using the United Network for Organ Sharing-Standard Transplant Analysis and Research (UNOS STAR) dataset, we reviewed data on 56,995 adult transplants (January 2002 through June 2013). A total of 3,170 NASH liver-only recipients were identified and were matched with 3,012 non-NASH HCV+ and 3,159 non-NASH HCV− controls [matched 1:1 based on gender, age at LT (±3 years), and MELD score (±3)]. Cox regression analysis revealed significantly lower hazard of all-cause (HR 0.669; P < 0.0001) and cardiovascular-related mortality (HR 0.648; P < 0.0001) in the NASH compared to the non-NASH group after adjusting for diabetes, BMI, and race. Relative to the non-NASH HCV-positive group, NASH group has lower hazard of all-cause (HR 0.539; P < 0.0001) and cardiovascular-related mortality (HR 0.491; P < 0001). A lower hazard of all-cause mortality (HR 0.844; P = 0.0094) was also observed in NASH patients compared to non-NASH HCV-negative group, but cardiovascular mortality was similar (HR 0.892; P = 0.3276). LT recipients with NASH have either lower or similar risk of all-cause and cardiovascular-related mortality compared to its non-NASH counterparts after adjusting for diabetes, BMI, and race.

UR - http://www.scopus.com/inward/record.url?scp=85025106071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025106071&partnerID=8YFLogxK

U2 - 10.1111/tri.13001

DO - 10.1111/tri.13001

M3 - Article

VL - 30

SP - 1051

EP - 1060

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 10

ER -